LBPO.TB01 · 肿瘤生物学 · Late-Breaking

胰腺内脂肪细胞通过抑制肿瘤免疫促进胰腺癌进展

Intra-pancreatic adipocytes promote pancreatic cancer progression by inhibiting tumor immunity

海报缩略图:胰腺内脂肪细胞通过抑制肿瘤免疫促进胰腺癌进展
编号 LB231 展板 6 时间 4/20 02:00–05:00 区域 Section 55 主讲 Chengcheng Wang, PhD
分会场 Late-Breaking Research: Tumor Biology 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Chengcheng Wang, Xinpeng Yin, Yupei Zhao

Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China

摘要 Abstract

中文摘要
引言:脂肪胰疾病(FPD)是最常见的胰腺疾病。据报道,FPD可能是胰腺癌的早期特异性先兆。胰腺癌是一种高度致命的恶性肿瘤,手术切除仍是唯一可能治愈的治疗方法。包括免疫治疗在内的其他治疗方式疗效有限,因此迫切需要探索新的治疗靶点。胰腺癌以独特的肿瘤微环境为特征,其中浸润的脂肪细胞与肿瘤进展密切相关。然而,其潜在机制仍不清楚。 研究依据:本研究旨在阐明脂肪细胞为何倾向于沉积在胰腺癌组织中,以及它如何促进胰腺癌进展。 结果:通过MRI影像分析(n=120)和切片H&E染色(n=71),我们发现与正常和良性胰腺肿瘤组相比,胰腺癌组的胰腺内脂肪分数显著增加。通过adipoq-cre谱系追踪小鼠模型,我们注意到胰腺癌所致脂肪细胞增加源于新生和转分化,而非胰腺常驻脂肪细胞的增殖。通过对患者和KPC小鼠模型病理切片的染色,我们发现浸润于胰腺癌内的脂肪细胞发生了棕色化。经实验验证,我们发现由胰腺癌细胞分泌的IGFBP2在肿瘤所致脂肪细胞棕色化中发挥关键作用。对胰腺癌患者和正常个体的胰腺内及胰周脂肪进行的单细胞核转录组测序(n=71)表明,浸润入胰腺癌的脂肪细胞在多个方面发生了改变,包括代谢通路和与其他细胞的相互作用。我们还发现,胰腺内的棕色化脂肪通过诱导免疫抑制性肿瘤微环境促进胰腺癌进展。最后,我们证明IGFBP2靶向治疗与抗PD1联合可有效抑制胰腺癌进展。 结论:我们发现胰腺癌细胞诱导脂肪细胞新生并沉积于胰腺中。同时,胰腺癌细胞还导致这些脂肪细胞发生棕色化。我们的发现证实棕色化的胰腺内脂肪细胞通过诱导免疫抑制性微环境促进胰腺癌进展。本研究系统描绘了胰腺内和胰周脂肪细胞的单细胞分辨图谱,建立了首个胰腺内及胰周脂肪的单细胞转录组数据库(https://pan-fatlas.com/),为脂肪研究领域提供了重要资源。靶向IGFBP2可能提供提升胰腺癌免疫治疗效率的治疗策略。
查看英文原文 English abstract
INTRODUCTION: Fatty pancreas diseases(FPD) is the most common disease of the pancreas. It is reported that FPD might be an early specific harbinger of pancreatic cancer. Pancreatic cancer is a highly lethal malignant tumor, and surgical resection remains the only possible curative treatment. The efficacy of other treatment modalities including immunotherapy is limited, making it urgent to explore novel therapeutic targets. Pancreatic cancer is characterized by a unique tumor microenvironment, where infiltrated adipocytes are closely associated with tumor progression. Albeit, the underlying mechanisms remain unclear. RATIONALE: This study aims to demonstrate why adipocyte prefer to deposit in pancreatic cancer tissue and how it contribute to the progression of pancreatic cancer. RESULTS: Using MRI imaging analysis(n=120) and H&E staining of sections(n=71), we found that the intrapancreatic fat fraction was significantly increased in the pancreatic cancer group compared with the normal and benign pancreatic tumor group. Through adipoq-cre linage tracing mouse model, we noticed that the increased adipocytes caused by pancreatic cancer originated from neogenesis and trans-differentiation rather than the proliferation of pancreatic resident adipocyte. By staining of the patient's and KPC mouse model pathological slides, we identified the adipocyte infiltrating within the pancreatic cancer underwent browning. After experimental verifications, we found IGFBP2, secreted by pancreatic cancer cells, played a crucial role in tumor caused adipocyte browning. Single-cell nuclear transcriptome sequencing(n=71) of intrapancreatic and peripancreatic fat in patients with pancreatic cancer and normal individuals indicated that the adipocytes infiltrating into pancreatic cancer had undergone changes in various aspects, including metabolic pathways and interactions with other cells. We also found that browning fat within the pancreas promotes the progression of pancreatic cancer by inducing an immunosuppressive tumor microenvironment. Finally, we demonstrated that the combination of IGFBP2 targeted therapy and anti-PD1 could effectively inhibit the progression of pancreatic cancer. CONCLUSIONS: We identified that pancreatic cancer cells induced adipocyte neogenesis and deposit in pancreas. At the same time, pancreatic cancer cells also caused these adipocytes to undergo browning. Our findings confirmed that the browning intrapancreatic adipocyte promoted the progression of pancreatic cancer by inducing an immune suppressive microenvironment. This study systematically depict the single cell resolved landscape of intrapancreatic and peripancreatic adipocytes, established the first single-cell transcriptome database(https://pan-fatlas.com/) for intra-pancreatic and peripancreatic fat which provided an important resource for fat research field. Targeting IGFBP2 may offer therapeutic strategies to boost immunotherapy efficiency in pancreatic cancer.
利益披露 Disclosure
C. Wang, None.. X. Yin, None.. Y. Zhao, None.

← 返回 AACR 2026 检索